Puerto Rican Alzheimer’s patients to be first in U.S. to obtain cannabis-based relief
Submitted by Marijuana News
India Globalization Capital, Inc. (NYSE American:IGC) – Alzheimer’s patients in Puerto Rico will be the first in the United States to obtain Hyalolex, IGC’s proprietary cannabinoid based formulation aimed at relieving many of the symptoms of Alzheimer’s Disease, such as agitation, anxiety, sleep disorder, as well as caregiver distress, among others.
Pursuant to an agreement between IGC and DaMa Pharmaceutical and its affiliates, Hyalolex will be on the shelves in April, and available to patients in ten of Puerto Rico’s 30 dispensaries, including the two premier dispensaries in San Juan, the largest city in Puerto Rico.
Under the licensing terms DaMa will help produce Hyalolex in Puerto Rico, and market Hyalolex to medical dispensaries and end users. Hyalolex will be prescribed as a liquid supplement in twice-daily doses for mild to moderate Alzheimer patients, and thrice-daily doses for moderate to advanced patients.
“We are very pleased to work with the DaMa Pharmaceutical team to bring Hyalolex to Puerto Rico, which has a long history of developing premier pharmaceutical products,” said Ram Mukunda CEO of IGC.
He noted that the Puerto Rican government has been a supporter of a comprehensive medical cannabis program. “We are proud to be a contributor to Puerto Rico’s economic development and to the wellbeing of its Alzheimer’s patients”, he said.
According to alz.org, Hispanics are approximately one and one-half times as likely to have Alzheimer’s as non-Hispanic whites.
“This is a decisive step in delivering our cannabis intellectual property to patients, after many years of development. It is particularly important as part of our effort to establish a distribution network to productize our IP,” Mukunda said.
This partnership represents a significant opportunity to provide those afflicted with Alzheimer’s with potential relief from a very difficult diagnosis and ease the burden of their caregivers who attend to them.
It also represents a significant opportunity to collect data on Hyalolex’s performance within a diverse patient set”, said Mukunda. IGC will deploy a QR code-based product assurance, information dissemination, and data collection system as a step towards a more robust block chain-based product assurance system.
Share on Facebook Tweet about this